-
Karen L Marquis,
Thomas A Comery,
Flora Jow, Rachel L Navarra,
Steven M Grauer,
Claudine Pulicicchio,
Cody Kelley,
Julie A Brennan,
Renza Roncarati,
Carla Scali,
Simon Haydar,
Chiara Ghiron,
Georg C Terstappen,
John Dunlop
[show abstract]
[hide abstract]
ABSTRACT: α7 nicotinic acetylcholine receptor (nAChR) agonists are proposed as candidate agents for the adjunctive treatment of cognitive deficits associated with schizophrenia. Despite the pursuit of such an approach clinically, it is surprising that the preclinical profile of pro-cognitive agents in conjunction with antipsychotic drugs is currently unexplored.
We determined if the memory-enhancing effects of the selective α7 nAChR agonist WYE-103914 were preserved in the presence of the atypical antipsychotic drug risperidone, and if the antipsychotic-like profile of risperidone was preserved in the presence of WYE-103914.
Using the rat novel object recognition (NOR) paradigm, the maintenance of memory-enhancing activity of the α7 nAChR agonist WYE-103914 in the presence of risperidone was examined. Similarly, in the standard tests of antipsychotic-like activity, apomorphine-induced climbing (AIC) in mice and conditioned avoidance responding (CAR) in rats, the preservation of antipsychotic-like activity of risperidone was evaluated in the presence of WYE-103914.
WYE-103914 exhibited memory-enhancing activity in rat NOR, and this effect of WYE-103914 was retained in the presence of risperidone. In AIC, the atypical antipsychotic profile of risperidone was not significantly altered by WYE-103914. In contrast, WYE-103914 moderately potentiated the efficacy profile of risperidone in CAR, an effect that did not appear to be convincingly linked to a pharmacokinetic interaction.
These data underscore the value of a preclinical evaluation of the adjunctive profile of a memory-enhancing agent in combination with antipsychotics and provide further support to augmentation with α7 nAChR agonists to address the cognitive deficits associated with schizophrenia.
Psychopharmacologia 06/2011; 218(4):635-47. · 4.08 Impact Factor
-
Michele P Kelly,
Sheree F Logue,
Julie Brennan,
Jonathon P Day,
Subha Lakkaraju,
Lixin Jiang,
Xiaotian Zhong,
May Tam,
Stacey J Sukoff Rizzo,
Brian J Platt, [......],
Sarah Neal,
Virginia L Pulito,
Michael J Agostino,
Steven M Grauer, Rachel L Navarra,
Cody Kelley,
Thomas A Comery,
Richard J Murrills,
Miles D Houslay,
Nicholas J Brandon
[show abstract]
[hide abstract]
ABSTRACT: Phosphodiesterase 11A (PDE11A) is the most recently identified family of phosphodiesterases (PDEs), the only known enzymes to break down cyclic nucleotides. The tissue expression profile of this dual specificity PDE is controversial, and little is understood of its biological function, particularly in the brain. We seek here to determine if PDE11A is expressed in the brain and to understand its function, using PDE11A(-/-) knockout (KO) mice. We show that PDE11A mRNA and protein are largely restricted to hippocampus CA1, subiculum, and the amygdalohippocampal area, with a two- to threefold enrichment in the ventral vs. dorsal hippocampus, equal distribution between cytosolic and membrane fractions, and increasing levels of protein expression from postnatal day 7 through adulthood. Interestingly, PDE11A KO mice show subtle psychiatric-disease-related deficits, including hyperactivity in an open field, increased sensitivity to the glutamate N-methyl-D-aspartate receptor antagonist MK-801, as well as deficits in social behaviors (social odor recognition memory and social avoidance). In addition, PDE11A KO mice show enlarged lateral ventricles and increased activity in CA1 (as per increased Arc mRNA), phenotypes associated with psychiatric disease. The increased sensitivity to MK-801 exhibited by PDE11A KO mice may be explained by the biochemical dysregulation observed around the glutamate alpha-amino-3-hydroxy-5-methyl-4-isozazolepropionic (AMPA) receptor, including decreased levels of phosphorylated-GluR1 at Ser845 and the prototypical transmembrane AMPA-receptor-associated proteins stargazin (gamma2) and gamma8. Together, our data provide convincing evidence that PDE11A expression is restricted in the brain but plays a significant role in regulating brain function.
Proceedings of the National Academy of Sciences 05/2010; 107(18):8457-62. · 9.68 Impact Factor
-
Julie A Brennan,
Radka Graf,
Steven M Grauer, Rachel L Navarra,
Claudine M Pulicicchio,
Zoë A Hughes,
Qian Lin,
Caitlin Wantuch,
Sharon Rosenzweig-Lipson,
Farhana Pruthi, [......],
Martina van de Neut,
Albert J Robichaud,
David Rotella,
Rolf W Feenstra,
Chris Kruse,
Pierre Broqua,
Chad E Beyer,
Andrew C McCreary,
Mark H Pausch,
Karen L Marquis
[show abstract]
[hide abstract]
ABSTRACT: The preclinical characterization of WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one] is described. In vitro binding and functional studies revealed highest affinity to the D(2) receptor (D(2L) K(i), 4.0 nM) and serotonin transporter (K(i), 7.1 nM), potent D(2) partial agonist activity (EC(50), 0.38 nM; E(max), 30%), and complete block of the serotonin transporter (IC(50), 56.4 nM). Consistent with this in vitro profile, WS-50030 (10 mg/kg/day, 21 days) significantly increased extracellular 5-HT in the rat medial prefrontal cortex, short-term WS-50030 treatment blocked apomorphine-induced climbing (ID(50), 0.51 mg/kg) in a dose range that produced minimal catalepsy in mice and induced low levels of contralateral rotation in rats with unilateral substantia nigra 6-hydroxydopamine lesions (10 mg/kg i.p.), a behavioral profile similar to that of the D(2) partial agonist aripiprazole. In a rat model predictive of antipsychotic-like activity, WS-50030 and aripiprazole reduced conditioned avoidance responding by 42 and 55% at 10 mg/kg, respectively. Despite aripiprazole's reported lack of effect on serotonin transporters, long-term treatment with aripiprazole or WS-50030 reversed olfactory bulbectomy-induced hyperactivity at doses that did not reduce activity in sham-operated rats, indicating antidepressant-like activity for both compounds. Despite possessing serotonin reuptake inhibitory activity in addition to D(2) receptor partial agonism, WS-50030 displays activity in preclinical models predictive of antipsychotic- and antidepressant efficacy similar to aripiprazole, suggesting potential efficacy of WS-50030 versus positive and negative symptoms of schizophrenia, comorbid mood symptoms, bipolar disorder, major depressive disorder, and treatment-resistant depression. Furthermore, WS-50030 provides a tool to further explore how combining these mechanisms might differentiate from other antipsychotics or antidepressants.
Journal of Pharmacology and Experimental Therapeutics 10/2009; 332(1):190-201. · 3.83 Impact Factor
-
David P Rotella,
Geraldine R McFarlane,
Alexander Greenfield,
Cristina Grosanu,
Albert J Robichaud,
Rajiah Aldrin Denny,
Rolf W Feenstra,
Sara Núñez-García,
Jan-Hendrik Reinders,
Martina van der Neut, [......],
Margaret Lai,
Jean Zhang,
Dianne M Kowal,
Tikva Carrick,
Steven M Grauer, Rachel L Navarra,
Radka Graf,
Julie Brennan,
Karen L Marquis,
Mark H Pausch
[show abstract]
[hide abstract]
ABSTRACT: A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D2 receptor ligands in an attempt to identify potent D2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D2 partial agonism in cell-based and in vivo assays.
Bioorganic & medicinal chemistry letters 09/2009; 19(19):5552-5. · 2.65 Impact Factor
-
Steven M Grauer,
Virginia L Pulito, Rachel L Navarra,
Michele P Kelly,
Cody Kelley,
Radka Graf,
Barbara Langen,
Sheree Logue,
Julie Brennan,
Lixin Jiang,
Erik Charych,
Ute Egerland,
Feng Liu,
Karen L Marquis,
Michael Malamas,
Thorsten Hage,
Thomas A Comery,
Nicholas J Brandon
[show abstract]
[hide abstract]
ABSTRACT: Following several recent reports that suggest that dual cAMP and cGMP phosphodiesterase 10A (PDE10A) inhibitors may present a novel mechanism to treat positive symptoms of schizophrenia, we sought to extend the preclinical characterization of two such compounds, papaverine [1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline] and MP-10 [2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline], in a variety of in vivo and in vitro assays. Both of these compounds were active in a range of antipsychotic models, antagonizing apomorphine-induced climbing in mice, inhibiting conditioned avoidance responding in both rats and mice, and blocking N-methyl-D-aspartate antagonist-induced deficits in prepulse inhibition of acoustic startle response in rats, while improving baseline sensory gating in mice, all of which strengthen previously reported observations. These compounds also demonstrated activity in several assays intended to probe negative symptoms and cognitive deficits, two disease domains that are underserved by current treatments, with both compounds showing an ability to increase sociality in BALB/cJ mice in the social approach/social avoidance assay, enhance social odor recognition in mice and, in the case of papaverine, improve novel object recognition in rats. Biochemical characterization of these compounds has shown that PDE10A inhibitors modulate both the dopamine D1-direct and D2-indirect striatal pathways and regulate the phosphorylation status of a panel of glutamate receptor subunits in the striatum. It is striking that PDE10A inhibition increased the phosphorylation of the (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor GluR1 subunit at residue serine 845 at the cell surface. Together, our results suggest that PDE10A inhibitors alleviate both dopaminergic and glutamatergic dysfunction thought to underlie schizophrenia, which may contribute to the broad-spectrum efficacy.
Journal of Pharmacology and Experimental Therapeutics 09/2009; 331(2):574-90. · 3.83 Impact Factor
